Monitor the June 12 KOL event for any incremental commentary on the LPCN 1154 regulatory path or partnership strategy. Without new data or a clear NDA timeline, this filing does not change the stock's risk/reward — any price move is likely noise. Watch for a subsequent 8-K if material regulatory developments follow.
Price Chart
Executive Summary
Lipocine filed an 8-K announcing a virtual KOL event on June 12, 2026, to discuss unmet needs in postpartum depression and Phase 3 topline results for LPCN 1154 (oral brexanolone). The event features prominent KOLs and management, but no new clinical data, regulatory milestones, or financial details are disclosed in the filing — the company is reiterating prior Phase 3 subgroup efficacy and safety data. This is a routine investor-awareness event with no material new information, making it neutral for traders.
Key Facts
- Virtual KOL event on June 12, 2026, at 11:00 AM Eastern Time
- Event will review LPCN 1154 Phase 3 topline results and PPD treatment landscape
- Phase 3 trial showed efficacy in a subgroup analysis excluding an epidemiologic outlier site
- 100% of participants completed dosing; no treatment-related serious adverse events
- LPCN 1154 is not yet FDA approved
- No new financial data, regulatory submissions, or business developments announced
Financial Impact
No financial figures disclosed; event is a clinical/regulatory update
Risk Factors
- LPCN 1154 faces uncertain FDA approval path with Phase 3 data limited to a subgroup analysis
- No disclosed partnership or financing catalyst; cash runway not addressed in this filing
- Stock is highly speculative with $18M market cap and no approved revenue-generating products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027209 |
| Exhibit: ex99-1.htm | 0001493152-26-027209 |
| Document: 0001493152-26-027209-index-headers.html | 0001493152-26-027209 |
| Document: 0001493152-26-027209-index.html | 0001493152-26-027209 |
| Document: 0001493152-26-027209.txt | 0001493152-26-027209 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $1.62 | awaiting T+60 | — | $1.47 (−9.25%) |
Oct 7, 2026 20d ago | 8-K | $2.20 | awaiting T+60 | — | $1.47 (−33.17%) |
Sep 16, 2026 5w ago | 8-K | $2.22 | awaiting T+60 | — | $1.47 (−33.77%) |
Sep 14, 2026 6w ago | 8-K | $2.22 | awaiting T+60 | — | $1.47 (−33.77%) |
Sep 11, 2026 6w ago | 8-K | $2.27 | awaiting T+60 | — | $1.47 (−35.23%) |
Sep 10, 2026 6w ago | 8-K | $2.25 | awaiting T+60 | — | $1.47 (−34.66%) |
Aug 4, 2026 12w ago | Press Release | $2.13 | awaiting T+60 | — | $1.47 (−30.98%) |
Aug 3, 2026 12w ago | 8-K | $2.11 | awaiting T+60 | — | $1.47 (−30.32%) |
Jun 4, 2026 20w ago | 8-K | $2.21 $2.17 | ▼ −1.81% | ▼ −3.69% | $1.47 (−33.48%) |
May 26, 2026 21w ago | 8-K | $2.28 $2.09 | ▼ −8.33% | ▼ −10.21% | $1.47 (−35.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers